Management of recurrent and/or metastatic HNSCC (50% of patients with locally advanced HNSCC will recur after primary treatment) that are not amenable to surgery and show PD-L1 expression are currently treated with Pembrolizumab + cisplatin and FU, showing an improvement in the overall survival (OS). The gene discussed is CD274; the disease is head and neck squamous cell carcinoma.